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Abstract
Background: Hypoxia inducible factor-1 alpha (HIF-1α) protein is rapidly degraded under
normoxic conditions. When oxygen tensions fall HIF-1α protein stabilizes and transactivates genes
involved in adaptation to hypoxic conditions. We have examined the normoxic expression of HIF1α RNA and protein in normal human melanocytes and a series of human melanoma cell lines
isolated from radial growth phase (RGP), vertical growth phase (VGP) and metastatic (MET)
melanomas.
Results: HIF-1α mRNA and protein was increased in RGP vs melanocytes, VGP vs RGP and MET
vs VGP melanoma cell lines. We also detected expression of a HIF-1α mRNA splice variant that
lacks part of the oxygen-dependent regulation domain in WM1366 and WM9 melanoma cells.
Over-expression of HIF-1α and its splice variant in the RGP cell line SbCl2 resulted in a small
increase in soft agar colony formation and a large increase in matrigel invasion relative to control
transfected cells. Knockdown of HIF-1α expression by siRNA in the MET WM9 melanoma cell line
resulted in a large decrease in both soft agar colony formation and matrigel invasion relative to cells
treated with non-specific siRNA. There is a high level of ERK1/2 phosphorylation in WM9 cells,
indicating an activated Ras-Raf-MEK-ERK1/2 MAPK pathway. Treatment of WM9 cells with 30 μM
U0126 MEK inhibitor, decreased ERK1/2 phosphorylation and resulted in a decrease in HIF-1α
expression. However, a 24 h treatment with 10 μM U0126 totally eliminated Erk1/2
phosphorylation, but did not change HIF-1alpha levels. Furthermore, siRNA knockdown of MEK
siRNA did not change HIF-1alpha levels.
Conclusion: We speculate that metabolic products of U0126 decrease HIF-1alpha expression
through "off target" effects. Overall our data suggest that increased HIF-1α expression under
normoxic conditions contributes to some of the malignant phenotypes exhibited by human
melanoma cells. The expanded role of HIF-1α in melanoma biology increases its importance as a
therapeutic target.

Background
The incidence of melanoma is increasing more rapidly
than any other tumor site. Melanoma accounts for 4% of

all skin cancers, but for 79% of all skin cancer related
deaths in the United States (Melanoma Research Foundation). Metastatic melanoma is highly resistant to both
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chemo- and radiotherapy [1]. Cutaneous melanoma
arises from, melanocytes, presumably due to early childhood exposure of the skin to UV radiation. A predisposing
factor for melanoma may be the melanocortin receptor. It
has been found that individuals having a mutation that
affects the function of the melanocortin receptor have an
increased risk of developing cutaneous melanoma [2].
Hypoxia-inducible factor-1 (HIF-1) is a master regulator
of O2 homeostasis in cells. It consists of a heterodimeric
transcriptional complex of two proteins, HIF-1β and HIF1α. HIF-1β is constitutively expressed whereas HIF-1α
protein is stabilized only under hypoxic conditions,
despite its continuous synthesis under normoxic conditions [3]. When O2 tension is normal, HIF-1冬 is hydroxylated at specific proline residues by the enzyme prolyl
hydroxylase-domain (PHD). This hydroxylation is
required for the von Hippel Lindau (VHL) tumor suppressor protein to bind to HIF-1α leading to subsequent ubiquitination and proteasome-targeted degradation [4]. VHL
binding is also enhanced by acetylation of lys532 catalyzed
by the acetyltransferase, ADP-ribosylation factor domain
protein 1 (ARD1) [5]. Under hypoxic conditions, proline
hydroxylation decreases thereby stabilizing HIF-1α,
which in turn moves to the nucleus and transactivates various genes containing hypoxia response elements [6].
HIF-1α controls the expression of over 60 genes involved
in many aspects of oncogenesis, including tumorigenesis
[7,8] anti-apoptosis [9,10], and genetic instability [11].
HIFα has also been implicated in the malignant progression of several cancers including mammary gland, prostate, brain, and lung [12]. HIF-1α is the regulatory subunit
of HIF-1. It is regulated at the protein level by both oxygen- dependent and independent pathways [6]. HIF-1α is
highly expressed in early stage of mouse hepatocarcinogenesis independent of hypoxia [13]. The hypoxia independent increase in HIF-1α is thought to be activated by
growth signaling pathways. A majority of human melanomas have constitutively active MAPK/extracellular signalregulated kinase (ERK) due to BRAF or N-Ras mutations
[14,15]. Activation of this pathway is correlated with the
upregulation of HIF-1α mRNA in human melanoma
[16,17]. However the biological significance of upregulated HIF-1α under normoxic conditions for initiation
and progression of melanoma has not been elucidated.
In this study, we examined the normoxic expression and
biological functions of HIF-1α in human melanoma. We
found that both full length and a splice variant, HIF1α785, are expressed in human melanoma cell lines while
essentially undetectable in normal human melanocytes.
Ectopic HIF-1α expression in a low expressing RGP cell
line stimulated Matrigel invasion, while knockdown of
HIF-1α in a high expressing MET cell line inhibited both
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soft agar colony formation and Matrigel invasion. Knockdown of MEK1/2 and loss of phosphorylated ERK1/2 did
not decrease HIF-1α expression. U0126 MEK inhibitor at
10 μM eliminated ERK1/2 phosphorylation, but did not
decrease HIF-1α expression.

Results

Expression of HIF-1α in human melanoma cells
In addition to the well known pathway of HIF-1alpha protein stabilization under hpoxic conditions, it has been
established that many oncoproteins and growth factor signaling pathways up-regulate HIF-1α expression under
normoxic conditions [18,19]. However, there are few
investigations into the normoxic expression of HIF-1α in
human melanoma and its role in the malignant progression of this disease. Here, we show that in human
melanoma cells, the oxygen-labile HIF-1α protein as well
as its mRNA is expressed endogenously under normoxic
conditions. Figure 1A shows that HIF-1α protein is highly
expressed in WM9 cells relative to normal human
melanocyte (HEMn-LP), but radial growth phase (SbCl2),
and vertical growth phase (WM1366) also express a
higher amount of HIF-1α protein relative to human

Figure 1 cells
Expression
melanoma
of HIF-1α protein in human melanocytes and
Expression of HIF-1α protein in human melanocytes
and melanoma cells. Nuclear extracts (30 μg) from
HEMn-LP (normal human melanocytes), SbCl2 (radial growth
phase melanoma), WM1366 (vertical growth phase
melanoma) and WM9 (metastatic melanoma) (A) and
WM3211 (radial growth phase melanoma), WM3248 (vertical growth phase melanoma), WM239 (metastatic melanoma)
(B) cell lines were analyzed by western blotting using a monoclonal anti-HIF-1α antibody (1 μg/ml). LaminB1 was used as
a loading control. This blot is representative of at least 3 different experiments, all of which gave similar results.
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melanocytes. Similar results are seen in second set of RGP,
VGP and MET melanoma cell lines (Fig. 1B). HIF-1α was
detected as 120 kD protein in nuclear extracts while no
protein was detected in cytoplasmic extracts (data not
shown).
Hypoxic stabilization of HIF-1α occurs at the protein level
[3]. Since HIF-1α protein was increased in human
melanoma cells under normoxic conditions, we determined whether this increase might be due to increased
HIF-1α mRNA levels. Initially we used semi-quantitative
RT-PCR to assess expression of HIF-1α full length (FL) and
a splice variant HIF-1α785 that is missing the acetylation
site lys532 due to lack of exon 11 (Fig. 2A). This splice variant encodes HIF-1α protein that has been reported to be
stable under normoxic conditions [17,20]. Primers were
designed so that full length HIF-1α would exclude HIF1α785 by targeting exon 11, which is absent in HIF1α785. Primers for HIF-1α785 excluded HIF-1α by targeting the exon 10:12 boundary only present in HIF-1α785.
Fig. 2B shows that human melanoma cell lines express
both full-length and the 785 splice variant HIF-1α mRNA
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at a level that appeared to be higher than normal human
melanocytes.
These findings were verified by qRT-PCR measurement of
full-length and HIF-1α785 mRNA levels (Fig. 3). All
melanoma cell lines had increased expression of HIF-1α
mRNA relative to normal human melanocytes. In addition VGP and MET cell lines expressed more of the 785
HIF-1α mRNA than full length HIF-1α mRNA. Overall the
WM9 metastatic melanoma expressed the highest amount
of 785 HIF-1α mRNA (~79× higher than normal human
melanocytes).
HIFαFL and HIF-1α785 gain-of-function in radial growth
phase SbCl2 cells
The level of HIF-1α protein is low in the radial growth
phase SbCl2 cells relative to VGP or MET cell lines. We
determined the effect of HIF-1αFL or HIF-1α785 overexpression on SbCl2 anchorage-independent growth and
Matrigel invasion. HIF-1αFL and HIF-1α785 were cloned
into the pLenti-V5-D-TOPO vector and transiently overexpressed in SbCl2 cells (Fig. 4A). HIF-1α785 overexpres-

Expression
Figure 2 of HIF-1αFL & HIF-α785 mRNA in human melanoma cells
Expression of HIF-1αFL & HIF-α785 mRNA in human melanoma cells. (A) Schematic representation of the functional domains of both HIF-1α full length and HIF-1α785. Both HIF-1αFL and 785 have various domains in common such as
basic helix loop helix (bHLH), Per/Arnt/Sim (PAS), Oxygen Dependent Degradation Domain (ODDD), N-terminal transactivation domain N-TAD, inhibitory domain (ID), nuclear localization signal (NLS) and C-terminal transactivation domain C-TAD.
Upon loss of exon 11 in HIF-1α785, part of the ODDD is deleted. This missing region contains the important lysine 532 residue
which is acetylated by ARD1 leading to increased stable interaction of HIF-1α with the von Hippel Lindau tumor suppressor.
This interaction directs HIF-1α to the ubiquitin-proteasome pathway for degradation under normoxic conditions [5]. (B) Total
RNA was extracted from HEMn-LP, SbCl2, WM1366, and WM9. RNA was reverse transcribed using the Advantage RT-for
PCR kit®. Five μL of the resulting cDNA was used in the PCR reaction as described in the Advantage cDNA kit® manual. Primers (see Methods for sequence) for HIF-1α and HIF-1α785 were designed to specifically amplify each variant with no crossamplification. Primers for the housekeeping control gene GAPDH were included in the Advantage cDNA kit®. Control primers
amplifying a fragment of the control plasmid included in the Advantage cDNA kit® were used to ensure optimal PCR conditions.
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Figure 3 analysis of HIF-1αFL & HIF-1α785 mRNA expression in human melanoma cells
Quantitative
Quantitative analysis of HIF-1αFL & HIF-1α785 mRNA expression in human melanoma cells. Total RNA was
extracted from HEMn-LP, SbCl2, WM1366, and WM9 cells at 72 h (A) after seeding. RNA was then converted to cDNA using
the High Capacity cDNA Archive Kit (ABI). Real-Time PCR analysis was performed using TaqMan probes directed at HIF-1αFL
or HIF-1α-785 as well as β-actin. The reactions were performed under conditions specified in the ABI TaqMan Gene Quantification assay protocol. Data was corrected for efficiency and loading using the Pfaffl method. Data is expressed as fold change,
corrected for β-actin, relative to HeMn-LP. (B) Real-time PCR analysis was performed using Taqman probes directed at HIF1αFL or HIF-1α785 as well as 18S using RNA extracted from HEMn-LP, WM3211, WM3248, and WM239 cells. Data is representative of at least 2 separate experiments.

sion resulted in a small, but statistically significant
increase in anchorage-independent growth, relative to
mock or lacz transfected cells (Fig. 4C and 4D). In contrast
overexpression of both HIF-1αFL and HIF-α785 in SbCl2
resulted in a large and significant 3-fold increase in
Matrigel invasion relative to mock or Lacz transfected cells
(Fig. 4B).
HIF-1α loss-of-function in human metastatic melanoma
WM9 cells
HIF-1α protein is highly expressed under normoxic conditions in the WM9 human metastatic melanoma cell line.
To determine whether HIF-1α could be contributing to
the malignant characteristics of these cells, we knocked
down its expression and examine how this affected

anchorage independent growth and Matrigel invasion.
WM9 cells were treated with 100 nM siRNA targeting HIF1α (Dharmacon) which consistently decreased its expression by ~75-85% (Fig. 5A). Colony formation after 5 days
in soft agarose was inhibited by 70% in HIF-1α-siRNA
transfected WM9 cells in comparison to cells transfected
with control siRNA (Fig. 5B). A photo (Fig. 5C) of the colonies formed at this time point in control vs. HIF-1α
transfected cells verifies this decrease in soft agar colony
formation. Matrigel invasion was also significantly
decreased in HIF-1α-siRNA transfected WM9 cells compared to control siRNA transfected WM9 cells (Fig. 5D).
Measurement of cell viability in the Matrigel chambers
shows no difference between control vs. HIF-1α siRNA
transfected cells (Fig. 5E). These knock down studies sug-
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invasion
Figure
Effect of4HIF-1αFL and HIF-1α785 overexpression in radial growth phase SbCl2 cells on anchorage-independent growth and
Effect of HIF-1αFL and HIF-1α785 overexpression in radial growth phase SbCl2 cells on anchorage-independent growth and invasion. SbCl2 cells were transiently transfected at 80% confluence with either mock (no plasmid DNA),
pLenti-V5-Lacz, pLenti-V5-D-TOPO-HIF-1αFL or pLenti-V5-D-TOPO-HIF-1α785 using FuGene 6 transfection reagent. (A)
After 48 h nuclear protein was extracted and over-expression was confirmed by western blot using HRP-conjugated anti-V5
antibody and mouse monoclonal anti-HIF-1α antibody (1 μg/ml). LaminB1 was used as loading control. (B) SbCl2 cells 24 h
post transfection with either mock (no plasmid DNA), Lacz, HIF-1αFL or HIF-1α785 were subjected to Matrigel invasion assay
as described in "Material and Methods". Results are expressed as percent invasive cells corrected for invasion level of cells
seeded in Matrigel (-) chambers. (C&D). SbCl2 cells transfected either with reagents alone (mock), Lacz, HIF-1αFL or HIF1α785 were subjected to CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs, Inc.) as described in "Material and
Methods" for 4 (C) and 5 days (D). Results are expressed as Relative Fluorescent Units. Data is expressed as the mean ± SEM
of triplicate values. ANOVA with TUKEY for multiple pairwise comparison was used to analyze the data and all P values ≤ 0.05
are relative to Mock and Lacz overexpressing cells. The entire experiment was repeated two additional times with similar
results.

gest that increased non-hypoxic expression of HIF-1α
plays an important role in key malignant properties
exhibited by these human melanoma cells.
Regulation of HIF-1α expression in human melanoma by
the ERK1/2 MAPK pathway
Hypoxia independent expression of HIF-1α is thought to
be regulated by growth signaling pathways [18,19] and
the majority of melanomas have constitutively active
ERK1/2 MAPK pathway due to BRAF or N-Ras mutations
[14,15]. Therefore, we determined whether HIF-1α
expression in human metastatic melanoma WM9 cells
was dependent on activation of ERK1/2 MAPK signaling.
These cells have an active ERK1/2 MAPK pathway as evidenced by the high phosphorylation of ERK (Fig. 6A).

Treatment of WM9 cells with 30 μM U0126, a selective
U0126 MEK inhibitor, decreased ERK1/2 phosphorylation and led to a time-dependent decrease in HIF-1α protein expression (Fig. 6A). Although 30 μM U0126 has
been used in published studies to selectively inhibit MEK
[16,21], the original paper describing this inhibitor [22]
used much lower concentrations to achieve high selectivity. Therefore we repeated this experiment using 10 μM
U0126 (Fig. 6B). At 24 h of treatment, 10 μM U0126 completely suppressed the phosphorylation of ERK1/2, yet
there was minimal change in the level of HIF-1α relative
to control cells. With further time of inhibitor treatment,
phosphorylation of ERK was not totally suppressed, but
HIF-1α levels decreased. We also used siRNA specifically
targeting MEK1 and 2 in WM9 cells to inhibit ERK1/2
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sion
Figure
The effect
5 of loss of HIF-1α expression in human metastatic melanoma WM9 cells on anchorage-independent growth and invaThe effect of loss of HIF-1α expression in human metastatic melanoma WM9 cells on anchorage-independent
growth and invasion. (A) WM9 cells were treated with either 100 nM HIF-1α siRNA or 100 nM control non-targeting
siRNA (Dharmacon, Inc.) using the RNAifect® transfection reagent (Qiagen, Inc.). Knock down of HIF-1α was confirmed by
western blot at 72 h post transfection. (B) At 48 h post transfection Ctrl siRNA or HIF-1α siRNA treated WM9 cells, were
assayed for anchorage independent growth using the CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs, Inc.). Briefly,
the cells were seeded at 8.0 × 103 cells/well into a 0.4% agar layer poured over a 0.6% agar layer of a 96 well plate. Wells lacking cells served as a blank control. On day 5 after seeding, agar layers were solubilized, cells were lysed, and nucleic acid stained
with CyQuant dye. Fluorescence intensity in each well was determined by a plate reader set at 485/520 nm. Results are
expressed as Relative Fluorescent Units. (C) Photomicrograph of a representative field of colonies form in the Cell Transformation Assay by control siRNA transfected cells (left) vs. HIF-1α siRNA transfected cells. (D) Matrigel invasion assay. At 48 h
post transfection, the Ctrl siRNA or HIF-1α siRNA transfected WM9 cells were seeded into 6-well Matrigel (+) chambers, and
as a control, 6-well Matrigel (-) chambers (BD Biosciences) at 7.0 × 104 cells per well. The method and counting of invading
cells was done as described in "Experimental Procedures". Results are expressed as % invasion of HIF-1α siRNA treated-WM9
cells relative to invasion by Control siRNA treated-WM9 cells corrected for invasion by similarly treated cells seeded in
Matrigel (-) chambers. (E) Cell viability assay was done in WM9 cells transfected with control siRNA or HIF-1α siRNA at 48,
72 and 96 h following transfection by the trypan blue exclusion method. Data is expressed as the mean ± SEM of triplicate samples. The entire experiment was repeated twice with similar results. Student paired t test was used to analyse the data and all
P values ≤ 0.01 or 0.05 are relative to control siRNA treated cells.

phosphorylation. Treatment of WM9 cells with siRNA targeting MEK1 and 2 consistently decreased its expression
by greater than 90% and also decreased ERK1/2 phosphorylation. However, knockdown of MEK1 and 2 did not
decrease the normoxic expression of HIF-1α protein in
human metastatic melanoma WM9 cells (Fig. 6C).

Discussion
Melanocytes - the cells responsible for producing the skincoloring pigment, melanin, are the point of origin for
melanoma. Melanoma, if diagnosed and treated early, has
a high cure rate [23]. If the melanoma progresses, it can
metastasize regionally to lymph nodes, and then to dis-
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tant organs such as the lungs, and the brain [24]. Metastatic melanoma is very difficult to treat and has a high
mortality rate. Several studies have confirmed that HIF-1α
is a survival factor, as well as a key regulator of metastasis
in various cancers [25,26].
HIF-1α regulates the adaptive responses to O2 tensions at
cellular levels. It controls the expression of many genes
involved in different aspects of tumor biology, including
angiogenesis, cell survival, invasion [3], tumor growth
[7,8], anti-apoptosis [9,10], and genetic instability [11].
HIF-1α is rapidly degraded under normoxic condition
and is stablilized under hypoxic condition [3]. We found
that HIF-1α protein and RNA is expressed under normoxic conditions in several human melanoma cell lines
and that the levels of HIF-1α expression correlates with
the stage of cancer from which the melanoma cell line was
established. In contrast, HIF-1α protein was undetectable
in normal human melanocytes. Normoxic expression of
HIF-1α has been found in a number of cancer cell types
[13,17,27]. Activation of the ERK1/2 MAPK [16] and
phosphotidylinositol 3-kinase (PI3K) [18] pathways has
been implicated in stimulating normoxic expression of
HIF-1α.

Figure
human
Effect ofmelanoma
6ERK1/2 MAPK
cells inhibition on HIF-1α expression in
Effect of ERK1/2 MAPK inhibition on HIF-1α expression in human melanoma cells. WM9 cells were treated
with either 30 (A) or 10 (B) μmol/L U0126 a MEK1/2-specific
inhibitor or vehicle (DMSO). Inhibition of ERK phosphorylation and HIF-1α expression was determined by western blotting at 24, 48 and 72 h after treatment using both total ERK,
phospho-specific ERK and HIF-1α antibodies respectively. C.
WM9 cells were also treated with either 100 nM MEK1&2
siRNA or 100 nM control non-targeting siRNA (Dharmacon,
Inc.) using the RNAifect® transfection reagent (Qiagen, Inc.).
Knock down of MEK1&2 was confirmed by western blot at
72 h post transfection. Inhibition of ERK phosphorylation and
HIF-1α expression was examined by western blot at the
same time point in nuclear extracts by using both total ERK,
phospho-specific ERK, and HIF-1α antibodies. The entire
experiment was repeated two additional times with similar
results.

The epidermis of the skin is a partial hypoxic environment
[28]. Evidence has been provided that this partial hypoxia
contributes to melanomagenesis [29,30]. Therefore, one
possibility is that the increase in HIF-1α that we observed
in melanoma ceils is due to the hypoxic adoptive response
maintained by the cells in culture. However, hypoxia stabilizes the HIF-1α protein and does not increase the level
of HIF-1α mRNA. We found that the increased HIF-1α
protein in the melanoma cells was correlated with an
increase in HIF-1α mRNA. Also, the normal human
melanocytes used in our study came from the partial
hypoxic environment of the skin and yet in culture, they
do not express detectable levels of HIF-1α protein. Therefore, we think it more likely that the increased HIF-1α
mRNA and protein is due to an inappropriately activated
signaling pathway.
We also found that an mRNA splice variant, HIF-1α785,
was expressed at higher levels than full length HIF-1α
mRNA in the VGP and metastatic human melanoma cell
lines. HIF-1α785 is missing the acetylation site lys532 due
to lack of exon 11 and is thought to be more stable under
normoxic conditions in comparison to full length HIF-1α
[17,20]. In several non-melanoma cell lines it was found
that phorbol ester stimulated the expression of HIF1α785 mRNA under normoxic conditions via a redoxdependent ERK1/2 MAPK pathway [17]. How this alternatively spliced isoform of HIF-1α mRNA is increased in
melanoma is currently under investigation.
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We examined the biological consequences of HIF-1α FL
and 785 splice variant gain of function and HIF-α FL loss
of function in selected human melanoma cells. The SbCl2
radial growth phase melanoma cells have low levels of
HIF-1α protein expression and a limited capacity to form
colonies in soft agar and to invade through Matrigel. This
cell line was chosen to determine the biological effects of
HIF-1α overexpression. Transient ectopic expression of FL
HIF-1α did not result in a statistically significant increase
in SbCl2 colony formation in soft agar. However, transient overexpression of HIF-1α785 resulted in a small, but
statistically significant increase in soft agar colony formation. The effect on anchorage-independent growth may be
limited by the transient nature of the overexpression of
HIF-1. Overexpression of either HIF-1αFL or 785 led to a
large and statistically significant increase in the ability of
SbCl2 cells to invade Matrigel. There have been a few
reports on the effect of HIF-1α overexpression on the in
vitro biologic properties of cancer cells. Hypoxia-induced
or exogenous overexpression of HIF-1α increased in vitro
invasion by human colon adenocarcinoma cells [31],
while stable normoxic overexpression of HIF-1α promoted anchorage-independent growth in melanocytes
having an activated AKT signaling pathway [30]. SbCl2
cells overexpressing HIF-1α785 showed a somewhat
greater increase in soft agar colony formation as well as
invasion ability compared to full length HIF-1α. Whether
this difference is due to a longer half-life for the splice variant protein relative to the full length protein is currently
under investigation.
HIF-1α loss of function experiments were carried out in
the WM9 metastatic melanoma cell line. This cell line was
chosen due to its high level of normoxic expression of
HIF-1α. The WM9 is an aggressive metastatic melanoma
cell line that has a high level of anchorage-independent
growth and Matrigel invasion ability. We found a significant decrease in both anchorage-independent growth and
Matrigel invasion upon silencing of normoxic expression
of HIF-1α by siRNA treatment. These decreases were not
due to a loss of cell viability as has been reported for
knockdown of HIF-1α under hypoxic conditions [16].
This decrease in invasion might be due to decreased
expression of HIF-1α regulated genes involved in invasion
such as matrix metalloproteinase 2 (MMP2), urokinase
plasminogen activator receptor (uPAR), and cathepsin D
[31,32]. Loss of anchorage-independent growth in HIF-1α
silenced cells may be due to ERK/MAPK, PI3K/Akt and
HIF-1 pathway interactions. The PI3K/Akt pathway is one
of the most critical pathways involved in anchorage-independent growth [33].
Hypoxia independent expression of HIF-1α is thought to
be regulated by growth signaling pathways [6]. The majority of melanomas have constitutively active ERK1/2 MAPK
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pathway due to BRAF or N-Ras mutations [14,15]. In particular, human metastatic melanoma WM9 cells have a
constitutively active ERK1/2 MAPK pathway most likely
due to the V600E BRAF mutation found in these cells.
Treatment of these cells with 30 μM of the selective MEK
inhibitor, U0126, decreased ERK1/2 phosphorylation and
also resulted in a time dependent decrease in HIF-1α protein expression.
This 30 μM concentration chosen for our initial studies
was based on two other published papers that used this
amount of U0126 to demonstrate the involvement of the
ERK1/2 MAPK pathway in the regulation of HIF-1α
[16,21]. In the original report describing U0126, it was
stated that the Ki for intracellular inhibition of ERK phosphorylation in COS-7 cells was 0.1 μM [22]. Thus the concentration used in our study and others [16,21] is 300
times higher than the Ki. Therefore we repeated the MEK
inhibition studies using 10 μM U0126. In contrast to 30
μM U0126, the lower concentration completely eliminated ERK1/2 phosphorylation after a 24 h incubation
with WM9 human metastatic melanoma cells. Despite
this inhibition of ERK1/2 phosphorylation, there was no
change in the expression of HIF-1α protein. At the later
time point of 48 and 72 h of inhibitor treatment the phosphorylation of ERK1/2 was not completely suppressed
and the level of HIF-1α protein was decreased. We also
inactivated ERK1/2 signaling by knocking down the
expression of MEK. We needed to use siRNA against both
MEK1 and MEK2 in order to obtain a > 90% decrease in
expression of these enzymes. Although this knockdown
inhibited ERK phosphorylation, there was no decrease in
HIF-1α protein expression at any time point assayed (up
to 6 days). In the course of analyzing these data, we were
informed by Promega, the manufacturer of U0126, that
the compound is unstable in tissue culture media and produces metabolites that have poor MEK inhibitory activity.
Considering the sum of our data, we hypothesize that the
metabolites of U0126 are responsible for the decrease in
HIF-1α protein levels. This would explain the lack of
change in HIF-1α protein in cells treated for 24 h with 10
μM U0126 despite complete inhibition of ERK1/2 phosphorylation and the fact that siRNA knockdown of MEK
resulting in decrease ERK1/2 phosphorylation also did
not result in a decrease in HIF-1α protein levels.
Analysis of BRAF and NRAS mutations in our human
melanoma cell lines (Table 1) shows that WM3211 cells
do not have the common activating mutations in these
genes, yet these cells express increased amounts of HIF-1α
protein and mRNA under normoxic conditions. Overall
our data suggest normoxic expression of HIF-1α is not regulated by the ERK1/2 MAPK pathway, at least in the WM9
human metastatic melanoma cell line. The hypoxia independent expression in melanoma cells, like other cancers,
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Table 1: Genotyping data of melanoma cell lines

Mutation
Cell lines

NRAS

Sbcl2

++

WM3211

WT/WT

V600E BRAF

V600D BRAF

(HEMn-LP) were derived from human foreskin (Cascade
Biologics, Portland, OR) and maintained in Medium 254
supplemented with 50 mL HMGS (Cascade Biologics,
Portland, OR) and 1 mL PSA solution (Cascade). Maintaining all cell lines in RPMI media for 48 h did not
change their level of HIF-1α expression levels

++

Materials and methods

Western Blot analysis
Nuclear extracts from each cell line were isolated using the
NePER kit® (Pierce, Rockford, IL) according to the manufacturers protocol. Protein concentration was determined
using the BCA protein assay reagents from Pierce as per
the manufacturer's instructions. Proteins were separated
by SDS-PAGE and transferred to nitrocellulose membranes using the BioRAD MiniProtean3® system. Equal
loading was also determined by Ponceau staining of the
nitrocellulose membranes. Blots were blocked using
ChemiBlocker reagent (Chemicon, Temecula, CA) for 1 hr
at room temperature and probed overnight at 4°C with
anti-HIF-1α mouse monoclonal antibody at 1 μg/mL
(R&D Systems, Minneapolis, MN), 1:1000 phospho-p44/
42 MAPK (Cell Signaling Tech Inc, Danvers, MA), p44/42
MAPK (Cell signaling Tech Inc, Danvers, MA), total
MEK1/2 (Cell Signaling Tech Inc, Danvers, MA), 1:2000
V5-HRP (Invitrogen, Carlsbad, CA), 1 μg/mL Lamin B1 or
Lamin A (Abcam, Cambridge, MA). Monoclonal mouse
secondary IgG antibody (GE Healthcare, Piscataway, NJ)
or rabbit secondary IgG antibody (Cell signaling) conjugated with HRP was applied after two 1× TBS + 0.05%
Tween (TBS-T) washes. Blots were incubated with secondary antibody at 1:3000 for 1 h at room temperature and
subsequently washed 2× with 1× TBS-T. A final 5 min
wash with TBS (no Tween) was performed just prior to
incubating the blot with ECL reagent (GE Healthcare, Piscataway, NJ). Blots were then autoradiographed and the
density of immunoreactive bands determined by a BioRad
imaging system after correction by an internal protein
standard such nuclear lamin.

Cell lines and cell culture conditions
SbCl2, WM3211 (RGP), WM1366, WM3248 (VGP), and
WM9, WM239 (Metastatic melanoma) cells were a generous gift from Meenhard Herlyn's lab at the Wistar Institute
(University of Pennsylvania). All cells were grown in a
humidified incubator with 5% CO2 and 95% air at 37°C.
The SbCl2 cells were cultured in MCDB153 media (Invitrogen, Carlesbad CA), supplemented with 2% fetal
bovine serum, 5 μg/ml insulin (Sigma Chemical, St.
Louis, MO), 1.68 mM CaCl2, 100 units/mL penicillin
streptomycin solution (Invitrogen Corp., Carlsbad CA).
WM3211 cells were cultured similar to Sbcl2 media except
for 5% fetal bovine serum and no CaCl2. WM1366,
WM3248, WM9 and WM239 cells were cultured in RPMI
medium (Invitrogen Corp., Carlsbad CA) supplemented
with 10% fetal bovine serum and 100 units/mL penicillin
streptomycin solution. Normal human melanocytes

RNA isolation and RT- PCR
Total RNA was extracted using Tri-Reagent (Sigma Chemical Co., St. Louis, MO). The purified RNA samples were
dissolved in RNase-free water and quantified by Nanodrop spectrophotometer (NanoDrop Technology, Inc.,
Wimington, DE). Each RNA sample had an A260/A280
ratio of 1.8 or above. The quality of RNA was determined
on the Agilent 2100 Bioanalyzer, using the RNA 6000
Nano Assay kit (Agilent Tehcnologies, Wilmington, DE)
and reverse transcribed using the RT-for-PCR kit (Clontech, Palo Alto, CA) as per manufacturer's instructions.
Primers were designed to either amplify only HIF-1α or
HIF-1α785 exclusively. HIF-1α primers excluded HIF1α785 by targeting exon 11, which is absent in HIF1α785. HIF-1α785 primers were designed to exclude HIF1α by targeting the exon 10:12 boundary only present in

WM1366

++

WM3248

++

WM9

++

WM239

++

The N-RAS or BRAF mutational status of melanoma cell lines RGP
(Sbcl2, WM3211), VGP (WM1366, WM3248), MET (WM9, WM239).

might be regulated by phosphotidylinositol 3-kinase
(PI3K) [13,18], NFkB [34] or JAK/STAT [35] pathways.

Conclusion
In conclusion, HIF-1α is overexpressed, in melanoma cell
lines under normoxic conditions in a manner that correlates with the aggressiveness of the tumor from which the
cell line was established. We also show that the novel
splice variant HIF-1α785, which is missing part of the oxygen regulation domain is overexpressed in these
melanoma cell lines. Manipulation of HIF-1α expression
in several of our melanoma cell lines suggests that this
transcription factors regulates, in part, anchorage-independent growth and Matrigel invasion. Our results suggest that development of new therapeutic agents that
inhibit HIF-1α function may be of use in the treatment of
human melanoma regardless of the hypoxic condition of
the tumor.
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HIF-1α785. Sequence of the HIF-1α forward primers
were: 5'-AAAGTTCACCTGAGCCTAAT-3', and reverse 5'TAAGAAAAAGCTCAGTTAAC-3'. The sequence of HIF1α785 forward primers were 5'-AAAGTTCACCTGAGGACAC-3', and reverse 5'-TAAGAAAAAGCTCAGTTAAC3'. Primers for the housekeeping gene control GAPDH
were included in the Advantage cDNA kit®. Control primers amplifying a fragment of the control plasmid included
in the Advantage cDNA kit® were used to ensure optimal
PCR conditions. PCR was performed using thermocycler
(Biometra Tgradient, Goettingen, Germany) conditions of
94°C for 1 min; 25 cycles of 94°C for 30 sec, 68°C for 4
min; 68°C for 5 min and 15°C soak.
For quantitative PCR, total RNA was extracted from the
different cell lines. RNA was then converted to cDNA
using the High Capacity cDNA Archive Kit (Applied Biosystems Inc. (ABI), Foster City, CA). qPCR analysis was
performed using TaqMan probes for HIF-1α (ABI Catalog
number Hs00936366) or HIF-1α785 (ABI Custom Primer
Order) as well as β-actin (ABI Catalog number
4326315E). The reactions were performed under conditions specified in the ABI TaqMan Gene Quantitation
assay protocol. Data was corrected for efficiency and loading using the Pfaffl method [36]. Data is representative of
at least 3 separate experiments.
DNA constructs
The pLenti-V5-D-TOPO vector was used in gain of function experiments in the SbCl2 radial growth phase human
melanoma cells. HIF-1α or HIF-1α785 was cloned into
this vector by amplifying these genes using primers specific for both the 5' and 3' ends of HIF-1α. The linearized
pLenti-V5-D-TOPO Vector contains 5' GTGG overhangs at
one end while the insert is Taq Amplified to contain a 5'
CACC overhang at one end. Following amplification, 20
μL of the 50 μL PCR amplification reactions were separated on a 1% agarose gel stained with ethidium bromide
to ensure that the correct size amplicon was present. HIF1α and HIF-1α785 amplicons were purified from the
remainder of the PCR reaction using the Zymo DNA
Clean & Concentrate Kit® (Zymo Research Inc., Orange,
CA). After ligation, plasmids were transformed into Stbl3
competent cells (Invitrogen Corp., Carlesbad, CA) and
plated onto agar plates containing 100 μg/mL ampicillin.
Plates were incubated at 37°C overnight and then colonies were screened for intact insert in the correct orientation. Plasmids were isolated from positive colonies and
analyzed by DNA sequencing to ensure the correct plasmid expression construct. Control plasmid, pLenti-V5LacZ, was supplied in the ViraPower kit® (Invitrogen
Corp., Carlsbad, CA).

http://www.molecular-cancer.com/content/8/1/104

Transient expression studies
SbCl2 cells were transfected at ~80% confluence with
either transfection reagent alone (mock), pLenti-LacZ,
pLenti-V5-D-TOPO-HIF-1α, or pLenti-V5-D-TOPO-HIF1α785 using FuGene 6 transfection reagent as per manufacturer's protocol (Roche, Palo Alto, CA). After 48 h protein was extracted and overexpression was confirmed by
western blot as described above.
siRNA inhibition of HIF-1α
WM9 cells seeded into 6 well plates at 2.0 × 105 were
treated 24 h after seeding with either 100 nM HIF-1α
siRNA or 100 nM control non-targeting siRNA (Dharmacon, Inc. Lafayette, CO) using the RNAifect® transfection reagent (Qiagen, Inc.) as per the manufacturer's
instructions. HIF-1α inhibition was confirmed by western
blotting at 48, 72, 96, and 120 h after transfection. There
was ~70% - 80% decrease in HIF-1α protein relative to
control siRNA treated WM9 cells at each time point. Cell
viability assays were performed using WM9 cells transfected with control siRNA or HIF-1α siRNA at 48, 72 and
96 h by the trypan blue exclusion method.
Matrigel invasion assay
SbCl2 cells overexpressing either HIF-1α, HIF-1α785, or
LacZ for 24 h, or WM9 cells transfected with Control
siRNA or HIF-1α siRNA for 48 h were seeded into 6-well
Matrigel (+) chambers, and, as a control, 6-well Matrigel
(-) chambers (BD Biosciences) at 7.0 × 104 cells per well.
At 24 hours post-seeding, the Matrigel was removed from
the chambers using a cotton-tipped applicator. After all
the Matrigel on the inner part of the chambers was
removed, invading cells were fixed with 80% methanol
for 5 minutes and then stained with 0.5% crystal violet for
5 minutes. After staining, the cells/chambers were extensively washed with distilled water. Once excess stain was
removed, cells were manually counted using a grid system
covering the entire lower surface of the chamber.
Anchorage-independent growth assay
CytoSelect 96 well Cell Transformation Assay® (Cell
Biolabs, Inc.) was used to determine anchorage-independent growth of SbCl2 cells overexpressing either HIF1α, HIF-1α785, or LacZ and WM9 cells transfected with
Control siRNA or HIF-1α siRNA. Cells were seeded at a
density of 1.0 × 104 into a 0.4% agar layer poured over a
0.6% agar layer in wells of a 96 well plate and incubated
for 4-5 days as per manufacturer's instructions. Wells lacking cells served as a fluorescent blank control. Agar layers
were solubilized, cells were lysed, and nucleic acid content stained with CyQuant dye. The amount of Cyquant
dye in each well was determined using a fluorescent plate
detector (Molecular Devices' Spectra Max GEMINI EM
Microplate spectrofluorometer; Biocompare Inc., CA) at
485/520 nm. Anchorage-independent growth of WM9
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cells transfected with Control siRNA or HIF-1α siRNA for
5 days was also confirmed by microscopic examination
(20×).
ERK inhibition
WM9 cells were seeded into 10 cm dishes at a density of
5.0 × 105 and the next day were treated with either 30 or
10 μmol/L U0126 (Promega, Madison, WI), a MEK1/2specific inhibitor to block ERK1/2 activation or vehicle
(DMSO). ERK inhibition was verified by western blotting
at 24, 48 and 72 h using both total and phospho-specific
ERK antibodies.

WM9 cells seeded into 6 well plates at 2.0 × 105 were
treated 24 h after seeding with either 100 nM MEK1 and
MEK2 siRNA or 100 nM control non-targeting siRNA
(Dharmacon, Inc. Lafayette, CO) using the RNAifect®
transfection reagent (Qiagen, Inc.) as per the manufacturer's instructions. Both MEK1 and MEK2 inhibition was
confirmed by western blotting at 72 h after transfection.
There was ~80 - 90% decrease in MEK1 and MEK2 protein
relative to control siRNA treated WM9 cells at each time
point.
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Statistics
Statistical analysis of the data was performed using the
student paired t test or ANOVA as appropriate. The statistical test used for each data set is stated in the figure legends; p < 0.05 was considered to be significant. Error bars
in all figures represent SEM.
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